ClinicalTrials.gg
TerminatedNCT03567291ARTISTSUpdated Nov 9, 2021Results posted

Evaluation of Safety and Tolerability of Long-term TEV-50717 (Deutetrabenazine) for Treatment of Tourette Syndrome in Children and Adolescents

A Phase 3 interventional study of TEV-50717 and Placebo in Tourette Syndrome, sponsored by Teva Branded Pharmaceutical Products R&D, Inc.. Terminated at 76 sites in 15 countries. Open to participants aged 6 Years to 17 Years. Per ClinicalTrials.gov, last updated 2021-11-09.

Sponsored by Teva Branded Pharmaceutical Products R&D, Inc. (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Why this study was terminated
The parent trials did not meet the primary endpoints of reduction in motor and phonic tics.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
228
Allocation
Randomized
Ages
6 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 139 studies in Tourette Syndrome with a site in United States — 20 open to participants now, 24 under way, 1 of them phase 3. Tourette Syndrome · United States.

Enrollment
6th of 105
228 · median 33
Started
2018
with 11 others
Phase 3
10 of 139
none open now
Registered
88th of 139
by date

Among the 139 studies in Tourette Syndrome with a site in United States, this one is the 6th largest by enrollment of the 105 interventional ones that give a count, is one of 12 that started in 2018, is one of 10 in phase 3, and was the 88th registered.

Tourette Syndrome

240 studies on the registry are indexed under Tourette Syndrome; 40 are open to participants now.

Browse Tourette Syndrome studies →

Open to participants now

20 of the 139 studies in Tourette Syndrome with a site in United States are open now. Recruiting first, the newest first:

15 more — sign in →

All 20 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 33 Tourette Syndrome studies recruiting now, 9 (27%) set no upper age limit and 22 (67%) stop at 75 or younger; 20 take children under 18; 9 take healthy volunteers.

This study: 6 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 139 studies in Tourette Syndrome with a site in United States, or all of them as a file.
02

Study summary

This is an otherwise open-label, single-arm study that includes a 2-week, double-blind, placebo controlled, randomized drug withdrawal period followed by a 3 week blinded maintenance or re-titration, and then a maintenance period. This study aims to evaluate the safety and efficacy of TEV-50717 tablets in patients with tics associated with TS who have previously completed participation in any of the parent studies.

Read the detailed description

This is an otherwise open-label, single-arm study (Part A) that includes a 2-week, double-blind, placebo controlled, randomized drug withdrawal period (Part B) followed by a 3 week blinded maintenance or re-titration (Part A resumed), and then a maintenance period. This study aims to evaluate the safety and efficacy of TEV-50717 tablets in patients with tics associated with TS who have previously completed participation in any of the parent studies (SD-809-C-17 [Phase 1b], TV50717-CNS 30046 [Phase 2/3], or TV50717-CNS 30060 [Phase 3]).

03

Conditions studied

  • Tourette Syndrome

Browse trials for

Keywords

  • adolescents
  • children
04

Who can participate

Ages eligible
6 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient is younger than 18 years of age on day 1
  • Patient weighs at least 44 pounds (20 kg)
  • The patient's active tics are causing distress or impairment
  • Patient is able to swallow study medication whole
  • Patient is in good general health
  • Women/girls of whose male partners are of childbearing potential must use for the duration of the study -- Additional criteria apply, please contact the investigator for more information

Exclusion criteria

Exclusion Criteria:

  • Patient is 18 years of age or older.
  • Patient has a neurologic disorder other than TS that could obscure the evaluation of tics.
  • The patient's predominant movement disorder is stereotypy (coordinated movements that repeat continually and identically) associated with autism spectrum disorder.
  • Patient has a confirmed diagnosis of bipolar disorder, schizophrenia, or another psychotic disorder.
  • Patient has depression at screening or day 1. Note: Patients receiving antidepressant therapy may be enrolled if on a stable dose for at least 6 weeks before screening.
  • Patient has a history of suicidal intent or related behaviors within 2 years of screening
  • Patient has a history of a previous actual, interrupted, or aborted suicide attempt.
  • Patient has a first-degree relative who has completed suicide.
  • Patient has clinically significant obsessive-compulsive disorder (OCD) on day 1 that, in the opinion of the investigator, is the primary cause of impairment.
  • Patient has received comprehensive behavioral intervention for tics for TS or cognitive behavioral therapy for OCD within 4 weeks of screening.
  • Patient has received treatment with deep brain stimulation, transmagnetic stimulation, or transcranial direct current stimulation for reduction of tics within 4 weeks of the screening visit.
  • Patient has an unstable or serious medical illness at screening or day 1
  • Patients with a history of torsade de pointes, congenital long syndrome, bradyarrhythmias, or uncompensated heart failure.
  • Patient has received a monoamine oxidase inhibitor within 14 days of the day 1 visit.
  • Patient has participated in an drug or device study (with the exception of Study SD-809-C-17, Study TV50717-CNS-30046, or Study TV50717-CNS-30060) and received IMP/intervention within 30 days or 5 drug half-lives of day 1, whichever is longer.
  • The patient is a pregnant or lactating female, or plans to become pregnant during the study.
  • Patient has a history of, or acknowledges, alcohol-related disorder in the previous 12 months -- Additional criteria apply, please contact the investigator for more information
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
228 participants (actual)

Study arms

  • Experimental
    TEV-50717- Part A

    All patients will undergo TEV-50717 dose titration in this study. Patients will receive 6 mg of TEV-50717 with food on the evening of day 1. The titration scheme and maximum dose will be determined by body weight and cytochrome P450 2D6 (CYP2D6) impairment status from the parent study.

    Drug: TEV-50717

  • Experimental
    TEV-50717- Part B RW

    TEV-50717 is administered during Part B Randomized Drug Withdrawal (RW) 2-week period.

    Drug: TEV-50717

  • Placebo comparator
    Placebo- Part B RW

    Placebo is administered during Part B Randomized Drug Withdrawal (RW) 2-week period only.

    Drug: Placebo

Interventions

  • DrugTEV-50717

    6, 9, and 12 mg oral tablets

    Also known as: deutetrabenazine, SD-809

  • DrugPlacebo

    Placebo comparator

06

What researchers measure

Primary outcomes

  1. Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined

    Adverse events were analyzed for all participants in Parts A \& B combined as one group for this outcome measure. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Incudes clinically significant changes such as changes in vital signs or lab values. Relationship of AE to treatment was determined by the Investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent the previously listed serious outcomes. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Day 1 to Week 55

  2. Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II)

    Adverse events were analyzed for Part B for this outcome measure. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Incudes clinically significant changes such as changes in vital signs or lab values. Relationship of AE to treatment was determined by the Investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent the previously listed serious outcomes. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Weeks 28 to 30

  3. Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score

    Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time." It contains 2 subscales (emotional problems and functional problem). Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors.

    Time frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55

  4. Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score

    CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills. Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks. It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems). Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children.

    Time frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55

  5. Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score at Week 30

    Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time." It contains 2 subscales (emotional problems and functional problem). Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors.

    Time frame: Week 28, Week 30

  6. Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score at Week 30

    CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills. Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks. It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems). Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children.

    Time frame: Week 28, Week 30

  7. Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)

    C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide. Number of participants with any suicidal ideation or suicidal behavior are reported. Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module.

    Time frame: Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55

  8. Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS) at Randomized Withdrawal Baseline Visit (Week 28) and Week 30

    C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide. Number of participants with any suicidal ideation or suicidal behavior are reported. Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module.

    Time frame: Week 28, Week 30

Secondary outcomes

  1. Change From Baseline in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)

    YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. Baseline is defined as the last measurement on or prior to the first dose of the open-label study medication.

    Time frame: Baseline, Weeks 8, 15, 28, 41, 54, and 55

  2. Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score

    The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. Baseline is defined as the last measurement on or prior to the first dose of the open-label study medication.

    Time frame: Baseline, Weeks 8, 15, 28, 41, 54, and 55

  3. Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score

    The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy. Baseline is defined as the last measurement on or prior to the first dose of the open-label study medication.

    Time frame: Baseline, Weeks 8, 15, 28, 41, 54, and 55

  4. Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score

    C\&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C\&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C\&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. Baseline is defined as the last measurement on or prior to the first dose of the open-label study medication.

    Time frame: Baseline, Weeks 6, 28, 34, 54

  5. Change From Randomized Withdrawal Baseline (Week 28) in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) to Week 30

    YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. The model is an ANCOVA model that includes fixed effects for treatment group. The randomized withdrawal baseline TTS and age group at baseline (2 levels: 6-11 years, 12-18 years) are included as covariates.

    Time frame: Week 28, Week 30

07

Results

Posted Mar 23, 2021

Participant flow

228 participants with Tourette Syndrome were enrolled after completing one of two eligible parent studies.

Period I
Participant flow — Period I
MilestoneTEV-50717Randomized TEV-50717Randomized PlaceboTEV-50717 Re-titration and Maintenance
Started228000
Safety set227000
Intent to treat set228000
Completed137000
Not completed91000
Withdrew: Adverse event14000
Withdrew: Protocol violation1000
Withdrew: Withdrawal by subject23000
Withdrew: Lost to follow-up2000
Withdrew: Terminated by sponsor44000
Withdrew: Missing or unknown7000
Period II
Participant flow — Period II
MilestoneTEV-50717Randomized TEV-50717Randomized PlaceboTEV-50717 Re-titration and Maintenance
Started091460
Completed088450
Not completed0310
Withdrew: Adverse event0100
Withdrew: Missing or unknown0210
Period III
Participant flow — Period III
MilestoneTEV-50717Randomized TEV-50717Randomized PlaceboTEV-50717 Re-titration and Maintenance
Started000133
Completed00048
Not completed00085
Withdrew: Adverse event0004
Withdrew: Withdrawal by subject0004
Withdrew: Lost to follow-up0001
Withdrew: Terminated by sponsor00068
Withdrew: Missing or unknown0008

Outcome measures

PrimaryNumber of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined

Adverse events were analyzed for all participants in Parts A \& B combined as one group for this outcome measure. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Incudes clinically significant changes such as changes in vital signs or lab values. Relationship of AE to treatment was determined by the Investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent the previously listed serious outcomes. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Day 1 to Week 55
Reported as:
Number · Participants
Number of Participants Reporting Treatment Emergent Adverse Events (AEs) for Parts A & B Combined
ParticipantsTEV-50717
At least one adverse event161
At least one serious adverse event2
At least one severe adverse event6
At least one AE related to investigational product95
At least one adverse event leading to withdrawal14
PrimaryNumber of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II)

Adverse events were analyzed for Part B for this outcome measure. An AE was defined as any untoward medical occurrence that develops or worsens in severity during the conduct of a clinical study and does not necessarily have a causal relationship to the study drug. Incudes clinically significant changes such as changes in vital signs or lab values. Relationship of AE to treatment was determined by the Investigator. Serious AEs include death, a life-threatening adverse event, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized the participant and required medical intervention to prevent the previously listed serious outcomes. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Weeks 28 to 30
Reported as:
Number · Participants
Number of Participants Reporting Treatment Emergent Adverse Events (AEs) in Part B (Period II)
ParticipantsRandomized TEV-50717Randomized Placebo
At least one adverse event166
At least one serious adverse event00
At least one severe adverse event00
At least one AE related to investigational product61
At least one adverse event leading to withdrawal00
PrimaryChange From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score

Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time." It contains 2 subscales (emotional problems and functional problem). Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors.

Time frame:
Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
Reported as:
Mean · Units On A Scale
Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score
Units On A ScaleTEV-50717
CDI-2 Parent Version Week 2-0.7 ± 4.26
CDI-2 Parent Version Week 4-1.5 ± 4.39
CDI-2 Parent Version Week 8-1.5 ± 5.0
CDI-2 Parent Version Week 15-1.2 ± 5.79
CDI-2 Parent Version Week 28-1.1 ± 5.52
CDI-2 Parent Version Week 34-1.0 ± 6.08
CDI-2 Parent Version Week 41-1.1 ± 5.92
CDI-2 Parent Version Week 54-0.3 ± 5.83
CDI-2 Parent Version Week 55-0.9 ± 4.34
PrimaryChange From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score

CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills. Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks. It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems). Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children.

Time frame:
Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
Reported as:
Mean · Units On A Scale
Change From Baseline in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score
Units On A ScaleTEV-50717
CDI-2 Self-reported Version Week 2-0.3 ± 3.41
CDI-2 Self-reported Version Week 4-0.5 ± 3.57
CDI-2 Self-reported Version Week 8-0.3 ± 4.35
CDI-2 Self-reported Version Week 15-0.3 ± 4.83
CDI-2 Self-reported Version Week 280.0 ± 4.65
CDI-2 Self-reported Version Week 34-0.5 ± 4.61
CDI-2 Self-reported Version Week 41-0.7 ± 4.74
CDI-2 Self-reported Version Week 54-0.5 ± 4.01
CDI-2 Self-reported Version Week 55-0.3 ± 4.52
PrimaryChange From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score at Week 30

Parents were asked to rate their child's behaviors in past 2 weeks on a 4-point Likert scale from "not at all" to "much or most of the time." It contains 2 subscales (emotional problems and functional problem). Total score: sum of 2 subscales, ranging from 0 to 51, with higher score indicating more depression-related behaviors.

Time frame:
Week 28, Week 30
Reported as:
Mean · Units On A Scale
Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score at Week 30
Units On A ScaleRandomized TEV-50717Randomized Placebo
Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Parent Version) Total Score at Week 30-0.2 ± 4.680.6 ± 3.62
PrimaryChange From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score at Week 30

CDI-2 self-report: 28-item questionnaire assessing depressive symptoms in children 7 to 17 years of age with basic reading and comprehension skills. Children were asked to choose 1 of 3 statements that most closely aligns with their feelings in past 2 weeks. It contains 6 subscales (emotional problem, negative mood/physical symptoms, negative self-esteem, functional problems, ineffectiveness, interpersonal problems). Total score: sum of all subscales scores, ranging from 0 to 56, with higher score indicating greater depression severity.CDI-2 parent: 17-item questionnaire administered to parents to assess depression-related behaviors observed in their children.

Time frame:
Week 28, Week 30
Reported as:
Mean · Units On A Scale
Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score at Week 30
Units On A ScaleRandomized TEV-50717Randomized Placebo
Change From Randomized Withdrawal Baseline (Week 28) in the Children's Depression Inventory Second Edition (CDI-2; Self-reported Version) Total Score at Week 30-0.4 ± 3.30-0.6 ± 3.08
PrimaryNumber of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)

C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide. Number of participants with any suicidal ideation or suicidal behavior are reported. Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module.

Time frame:
Baseline, Weeks 2, 4, 8, 15, 28, 34, 41, 54, 55
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS)
ParticipantsTEV-50717
Baseline0
Week 20
Week 42
Week 80
Week 151
Week 280
Week 340
Week 411
Week 540
Week 550
PrimaryNumber of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS) at Randomized Withdrawal Baseline Visit (Week 28) and Week 30

C-SSRS included responses for Suicidal Ideation or Suicidal Behavior in following 10 categories: 1 = Wish to be dead; 2 = Non-specific active suicidal thoughts; 3 = Active suicidal ideation with any methods (not plan) without intent to act; 4 = Active suicidal ideation with some intent to act, without specific plan; 5 = Active suicidal ideation with specific plan and intent; 6 = Preparatory acts or behavior; 7 = Aborted attempt; 8 = Interrupted attempt; 9 = Non-fatal suicide attempt; and 10 = Completed suicide. Number of participants with any suicidal ideation or suicidal behavior are reported. Any Suicidal ideation or Suicidal Behavior events reported as TEAEs along with all other reported TEAEs are included in the AE module.

Time frame:
Week 28, Week 30
Reported as:
Count of participants · Participants
Number of Participants Reporting Any Suicidal Ideation or Suicidal Behavior According to the Columbia Suicide Severity Rating Scale (C-SSRS) at Randomized Withdrawal Baseline Visit (Week 28) and Week 30
ParticipantsRandomized TEV-50717Randomized Placebo
Week 2800
Week 3000
SecondaryChange From Baseline in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)

YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. Baseline is defined as the last measurement on or prior to the first dose of the open-label study medication.

Time frame:
Baseline, Weeks 8, 15, 28, 41, 54, and 55
Reported as:
Mean · Units on a scale
Change From Baseline in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS)
Units on a scaleTEV-50717
Week 8-6.9 ± 0.58
Week 15-7.8 ± 0.58
Week 28-6.2 ± 0.83
Week 41-8.3 ± 0.97
Week 54-6.5 ± 1.47
Week 55-4.3 ± 1.6
SecondaryChange From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score

The TS-CGI scale is a 7-point Likert scale that allows the clinician to use all available information to assess the impact of tics on the participant's quality of life. The TS-CGI is rated as follows: 1 (normal or no tics at all), 2 (borderline), 3 (mild), 4 (moderate), 5 (marked), 6 (severe), and 7 (extreme, incapacitating tics). Lower scores indicate better quality of life. Baseline is defined as the last measurement on or prior to the first dose of the open-label study medication.

Time frame:
Baseline, Weeks 8, 15, 28, 41, 54, and 55
Reported as:
Mean · Units on a scale
Change From Baseline in the Tourette Syndrome-Clinical Global Impression (TS-CGI) Score
Units on a scaleTEV-50717
Week 8-0.7 ± 0.06
Week 15-0.7 ± 0.06
Week 28-0.6 ± 0.08
Week 41-0.6 ± 0.1
Week 54-0.8 ± 0.16
Week 55-0.4 ± 0.15
SecondaryChange From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score

The TS-PGII is a single-item questionnaire that asks the participant to assess the degree of impact due to current tics (How much do your current tics disrupt things in your life?). The TS-PGII uses a 5-point scale, ranging from not at all (1) to very much (5), to assess overall response to therapy. Baseline is defined as the last measurement on or prior to the first dose of the open-label study medication.

Time frame:
Baseline, Weeks 8, 15, 28, 41, 54, and 55
Reported as:
Mean · Units on a scale
Change From Baseline in the Tourette Syndrome-Patient Global Impression of Impact (TS-PGII) Score
Units on a scaleTEV-50717
Week 8-0.5 ± 0.07
Week 15-0.5 ± 0.08
Week 28-0.5 ± 0.09
Week 41-0.6 ± 0.12
Week 54-0.5 ± 0.16
Week 55-0.1 ± 0.14
SecondaryChange From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score

C\&A-GTS-QOL is a 27-item questionnaire that asks participant to assess the extent to which their quality of life is impacted by their symptoms. C\&A-GTS-QOL contains 6 subscales (cognitive, coprophenomena, psychological, physical, obsessive-compulsive, and ADL) and uses a 5-point Likert scale ranging from no problem to extreme problem. Following 3 questions from 27-item questionnaire were assessed in ADL C\&A-GTS-QOL subscale: Question 2 (Had difficulty with school or sport activities?), 24 (Felt you needed more help or support from other people?), and 26 (Had difficulty going out with other people?). Total score of ADL subscale ranged from 0 (no problem) to 12 (extreme problem). Lower score indicated better quality of life. Baseline is defined as the last measurement on or prior to the first dose of the open-label study medication.

Time frame:
Baseline, Weeks 6, 28, 34, 54
Reported as:
Mean · Units on a scale
Change From Baseline in the Child and Adolescent Gilles de la Tourette Syndrome - Quality of Life (C&A-GTS-QOL) Activities of Daily Living (ADL) Subscale Score
Units on a scaleTEV-50717
Week 6-4.9 ± 1.12
Week 28-4.4 ± 1.48
Week 34-5.9 ± 1.82
Week 54-2.7 ± 2.1
SecondaryChange From Randomized Withdrawal Baseline (Week 28) in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) to Week 30

YGTSS rating scale is a semi-structured clinician rating instrument that provides an evaluation of the number, frequency, intensity, complexity, and interference of motor and phonic tics. YGTSS is composed of 11 items: 5 items for motor tic severity, 5 items for vocal tic severity, and 1 item for impairment. Each item for motor tic severity and vocal is rated on a 6-point scale (0 for none to 5 to severe). MTSS is the sum of the 5 items for motor tic severity and VTSS is the sum of the 5 items for vocal tic severity. TTS is the sum of MTSS and VTSS, ranges from 0 (none/absent) to 50 (severe). Higher scores indicate greater severity/worse outcome. The model is an ANCOVA model that includes fixed effects for treatment group. The randomized withdrawal baseline TTS and age group at baseline (2 levels: 6-11 years, 12-18 years) are included as covariates.

Time frame:
Week 28, Week 30
Reported as:
Least squares mean · Units on a scale
Change From Randomized Withdrawal Baseline (Week 28) in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) to Week 30
Units on a scaleRandomized TEV-50717Randomized Placebo
Change From Randomized Withdrawal Baseline (Week 28) in the Yale Global Tic Severity Scale (YGTSS) Total Tic Score (TTS) to Week 301.6 ± 0.862.0 ± 1.24
Statistical analysis
  • Randomized TEV-50717 vs Randomized Placebo · ANCOVA · p = 0.78 · Mean difference (final values): -0.4 · 95% CI -3.4 to 2.6

Adverse events

Collected over Baseline to Week 55. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Total0/227 (0%)2/227 (0.9%)108/227 (47.6%)
Most frequent serious events
Most frequent serious events
EventTotal
Abdominal pain upperGastrointestinal disorders1/227
Self-injurious ideationPsychiatric disorders1/227
Most frequent other events
Most frequent other events
EventTotal
HeadacheNervous system disorders30/227
SomnolenceNervous system disorders28/227
NasopharyngitisInfections and infestations23/227
Weight increasedInvestigations22/227
AnxietyPsychiatric disorders17/227
VomitingGastrointestinal disorders15/227
TicPsychiatric disorders15/227
PyrexiaGeneral disorders13/227

Baseline characteristics

Intent-to-treat (ITT) analysis set included all enrolled participants.

Age, Continuous
Age, Continuous(Years)All Participants
Mean12 ± 2.59
Sex/Gender, Customized
Sex/Gender, Customized(Participants)All Participants
Participants — Male182
Participants — Female45
Participants — Unknown1
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)All Participants
Hispanic or Latino38
Not Hispanic or Latino186
Unknown or Not Reported4
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)All Participants
White197
Black4
Asian7
Native American5
Other15
08

Study locations

76 sites
  • Teva Investigational Site 046-0104
    Dothan, Alabama 36303, United States
  • Teva Investigational Site 046-0107
    Rogers, Arkansas 72758, United States
  • Teva Investigational Site 046-0126
    Anaheim, California 92805, United States
  • Teva Investigational Site 046-0101
    Sacramento, California 95815, United States
  • Teva Investigational Site 046-0111
    San Diego, California 92108, United States
  • Teva Investigational Site 060-0160
    Gainesville, Florida 32608, United States
  • Teva Investigational Site 060-0166
    Gulf Breeze, Florida 32561-4458, United States
  • Teva Investigational Site 060-0161
    Miami, Florida 33136-2107, United States
  • Teva Investigational Site 046-0115
    Orlando, Florida 32803, United States
  • Teva Investigational Site 060-0153
    Orlando, Florida 32819, United States
  • Teva Investigational Site 046-0114
    Saint Petersburg, Florida 33701, United States
  • Teva Investigational Site 046-0116
    Atlanta, Georgia 30331, United States
  • Teva Investigational Site 060-0155
    Chicago, Illinois 60612, United States
  • Teva Investigational Site 060-0164
    Chicago, Illinois 60634, United States
  • Teva Investigational Site 046-0133
    Naperville, Illinois 60563, United States
  • Teva Investigational Site 046-0128
    Boston, Massachusetts 02114, United States
  • Teva Investigational Site 060-0170
    Bridgeton, Missouri 63044, United States
  • Teva Investigational Site 046-0110
    Saint Charles, Missouri 63304, United States
  • Teva Investigational Site 046-0134
    Lincoln, Nebraska 68526-9467, United States
  • Teva Investigational Site 046-0109
    Voorhees, New Jersey 08043, United States
  • Teva Investigational Site 046-0124
    New York, New York 10029, United States
  • Teva Investigational Site 060-0154
    New York, New York 10036, United States
  • Teva Investigational Site 046-0102
    Rochester, New York 14618, United States
  • Teva Investigational Site 046-0106
    Oklahoma City, Oklahoma 73116, United States
  • Teva Investigational Site 060-0169
    Charleston, South Carolina 29414-5834, United States
  • Teva Investigational Site 060-0156
    Nashville, Tennessee 37232-2551, United States
  • Teva Investigational Site 046-0113
    Dallas, Texas 75243, United States
  • Teva Investigational Site 060-0163
    Fort Worth, Texas 76104, United States
  • Teva Investigational Site 046-0108
    Houston, Texas 77030, United States
  • Teva Investigational Site 046-0120
    San Antonio, Texas 78249, United States
  • Teva Investigational Site 046-0105
    Orem, Utah 84058, United States
  • Teva Investigational Site 046-0118
    Petersburg, Virginia 23805, United States
  • Teva Investigational Site 060-0162
    Everett, Washington 98201-4077, United States
  • Teva Investigational Site 060-1407
    Buenos Aires, C1023AAB, Argentina
  • Teva Investigational Site 060-1402
    Buenos Aires, C1425AHQ, Argentina
  • Teva Investigational Site 060-1403
    La Plata, 1900, Argentina
  • Teva Investigational Site 060-1404
    Mendoza, 5500, Argentina
  • Teva Investigational Site 060-1802
    Liverpool, 2170, Australia
  • Teva Investigational Site 046-0201
    Ajax, Ontario L1Z0M1, Canada
  • Teva Investigational Site 046-0202
    Ottawa, Ontario K2G 1W2, Canada
  • Teva Investigational Site 060-1503
    Bello, 051050, Colombia
  • Teva Investigational Site 060-1504
    Pereira, 660003, Colombia
  • Teva Investigational Site 046-0302
    Herlev, 2730, Denmark
  • Teva Investigational Site 046-0301
    Odense, 5000, Denmark
  • Teva Investigational Site 060-0901
    Budapest, 1021, Hungary
  • Teva Investigational Site 060-0902
    Szeged, 6725, Hungary
  • Teva Investigational Site 060-1005
    Cagliari, 09121, Italy
  • Teva Investigational Site 060-1001
    Catania, 95123, Italy
  • Teva Investigational Site 060-1003
    Naples, 80131, Italy
  • Teva Investigational Site 060-1901
    Seoul, 110-744, Korea, Republic of
  • Teva Investigational Site 060-1903
    Seoul, 138-736, Korea, Republic of
  • Teva Investigational Site 060-1902
    Seoul, 6351, Korea, Republic of
  • Teva Investigational Site 060-1601
    Culiacan, 80020, Mexico
  • Teva Investigational Site 060-1603
    Leon, 37000, Mexico
  • Teva Investigational Site 060-1602
    Monterrey, 64460, Mexico
  • Teva Investigational Site 060-1604
    Monterrey, 64610, Mexico
  • Teva Investigational Site 060-1104
    Gdansk, 80-542, Poland
  • Teva Investigational Site 060-1101
    Katowice, 40-123, Poland
  • Teva Investigational Site 060-1105
    Krakow, 31503, Poland
  • Teva Investigational Site 060-1102
    Poznan, 60-693, Poland
  • Teva Investigational Site 060-1103
    Warsaw, 02-793, Poland
  • Teva Investigational Site 046-0704
    Tomsk, 634050, Russian Federation
  • Teva Investigational Site 046-0703
    Voronezh, 394024, Russian Federation
  • Teva Investigational Site 046-1702
    Belgrade, 11000, Serbia
  • Teva Investigational Site 046-1703
    Belgrade, 11000, Serbia
  • Teva Investigational Site 046-1701
    Novi Sad, 21000, Serbia
  • Teva Investigational Site 046-0605
    Madrid, 28009, Spain
  • Teva Investigational Site 046-0602
    Madrid, 28922, Spain
  • Teva Investigational Site 046-0603
    Malaga, 29620, Spain
  • Teva Investigational Site 046-0601
    Sevilla, 41013, Spain
  • Teva Investigational Site 060-2003
    Dnipropetrovsk, 49101, Ukraine
  • Teva Investigational Site 060-2001
    Kharkiv, 61068, Ukraine
  • Teva Investigational Site 060-2002
    Kharkiv, 61153, Ukraine
  • Teva Investigational Site 060-2007
    Kiev, 4080, Ukraine
  • Teva Investigational Site 060-2005
    Kyiv, 4209, Ukraine
  • Teva Investigational Site 060-2006
    Vinnytsia, 21005, Ukraine
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from May 2018 to primary completion in May 2020, 23 months.

Results were first posted in Mar 2021, 10 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 12, 2018
First posted
Jun 25, 2018
StartActual
May 25, 2018
Primary completionActual
May 15, 2020
CompletionActual
May 15, 2020
Results first posted
Mar 23, 2021
Last update
Nov 9, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 9, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03567291
Collaborators
Nuvelution TS Pharma, Inc.
Responsible party
Sponsor
First posted
Jun 25, 2018
Start date
May 25, 2018
Primary completion
May 15, 2020
Completion
May 15, 2020
Results posted
Mar 23, 2021
Last update
Nov 9, 2021

Study contacts

Teva Medical Expert, MD
study director · Teva Branded Pharmaceutical Products R&D, Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Nov 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion